All Substitutes
Loading...
Disclaimer
Did you find this information helpful?
Suregraft 0.50mg Tablet
Prescription Required
Salt Composition : Everolimus
Manufacturer : HOSPIMAX HEALTHCARE PVT LTD
Origin of Medicine : India
10 Tablet(s) In A Strip
Introduction to Suregraft 0.50mg Tablet
Suregraft 0.50mg Tablet is an antineoplastic drug belonging to the class of mTOR inhibitors, containing the active ingredient everolimus. It is used to treat advanced breast cancer, renal cell carcinoma, pancreatic neuroendocrine tumours, and also in the treatment of subependymal giant cell astrocytoma(tumours are found in the ventricles of the brain). Good oral hygiene and regular dental check-ups is important during the treatment since this medicine can cause sores or ulcers in the mouth.
It is often combined with cyclophosphamide, an alkylating agent, to treat subependymal giant cell astrocytoma. Before taking this medicine, it is necessary to know that your risk of getting bacterial or viral infection increases with this treatment. If you have been infected with Hepatitis B, Suregraft 0.50mg Tablet increases the chances of reinfection. Tell your healthcare provider if you experience fever, chills, cough, yellowing of skin, joint pain or swelling during this treatment. You must limit your exposure to sunlight and UV light by wearing protective clothing and applying sunscreen frequently, as this medicine may increase the risk of developing cancers. Avoid taking grapefruit juice or grapefruit while taking this medicine.
Suregraft 0.50mg Tablet are not recommended for adolescents and children under the age of 18. Contact your doctor immediately if you experience shortness of breath, chest pain or worsening cough. During the Suregraft 0.50mg Tablet treatment, your doctor may periodically monitor your white blood cell counts, platelets, blood sugar, electrolytes and kidney parameters to prevent serious complications. This medicine has the potential to cause kidney problems. Report to your doctor if you have been diagnosed with liver disorders, heart failure, high blood cholesterol levels, or hypertension before starting this treatment. Avoid live vaccines and close contact with those who have received live vaccines.
Uses of Suregraft 0.50mg Tablet
- Advanced breast cancer
- Advanced renal cell carcinoma
- Advanced pancreatic neuroendocrine tumours
- Treatment of subependymal giant cell astrocytoma
Therapeutic Effects of Suregraft 0.50mg Tablet
It contains the active ingredient Suregraft 0.50mg Tablet, which inhibits the activity of a protein called mammalian target of rapamycin (mTOR), which regulates cell growth. This drug can slow the growth of abnormal cancer cells by blocking the mTOR protein. Suregraft 0.50mg Tablet helps to reduce the size of tumours and improve outcomes in patients.
Interaction of Suregraft 0.50mg Tablet with other drugs
Inform your healthcare provider about all the medicines you take, including prescription medications, over-the-counter medications, nutritional or vitamin supplements, and herbal products. Certain medications may interact with Suregraft 0.50mg Tablet and reduce effectiveness by causing undesirable side effects.
More Information about Suregraft 0.50mg Tablet
- Store Suregraft 0.50mg Tablet in the original package at room temperature (20°C to 25°C).
- Do not freeze.
- Keep it out of reach from children.
How to consume Suregraft 0.50mg Tablet
Your doctor will decide the dose and duration of Suregraft 0.50mg Tablet based on the disease condition and other factors. Always take this medicine as prescribed by your doctor. Take the tablet at the same time everyday, with or without food. Do not chew, crush, or break the tablet. Swallow the whole tablet with water. If you forgot to take the tablet, simply take your next dose at the scheduled time. Do not take a double dose to make up for a forgotten dose.
Safety Advices for Suregraft 0.50mg Tablet
Pregnancy
Suregraft 0.50mg Tablet is not recommended for pregnant women as it may cause fetal harm. Consult your doctor if you are pregnant or planning for pregnancy during the treatment.
Breast Feeding
It is not known if Suregraft 0.50mg Tablet passes into your breast milk or if it will affect your baby. Please consult your doctor before breastfeeding.
Lungs
It is not known whether Suregraft 0.50mg Tablet can be administered to patients with lung problems. Consult your doctor if you have any lung diseases before starting the treatment.
Liver
Inform your doctor if you have any liver problems before taking Suregraft 0.50mg Tablet. Regular monitoring of liver function tests is recommended.
Alcohol
Consuming alcohol may affect the effectiveness of Suregraft 0.50mg Tablet. Stop consuming alcohol if you are taking this medicine.
Driving
It is unsafe to drive vehicles or operate heavy machinery after taking Suregraft 0.50mg Tablet, it may cause dizziness and impair your concentration.
Side Effects of Suregraft 0.50mg Tablet
Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them.
Serious:
- Difficulty breathing, or swallowing
- Swelling of face, lips, tongue, throat
- Severe itching, red rash, raised bumps
Common:
- Infection (chills, increased temperature)
- Coughing
- Wheezing
- Excessive thirst
- High urine output or severely decreased urine output
- Tiredness
- Bleeding
- Increased appetite with weight loss
Word of Advice
Suregraft 0.50mg Tablet have the tendency to cause harm to unborn foetus. Inform your healthcare provider before starting this treatment if you are pregnant, or have a partner who can become pregnant. Your health care provider will conduct a pregnancy test before you start treatment with Suregraft 0.50mg Tablet. Discuss effective birth control methods with your healthcare provider and use them during treatment and for 8 weeks after your last dose. It is not known if Suregraft 0.50mg Tablet passes into the breast milk. Hence, it is not recommended to breastfeed during this treatment. Occurrence of mouth ulcers or sores are pretty common during this treatment, so your healthcare provider will prescribe a mouthwash. Use the mouthwash as recommended which helps prevent and manage the symptoms.
FAQs
Q 1. What you should know before taking Suregraft 0.50mg Tablet?
Before taking Suregraft 0.50mg Tablet, it is important to know that your risk of getting bacterial or viral infection increases with this treatment. If you have been infected with Hepatitis B, Suregraft 0.50mg Tablet increases the chances of reinfection. Tell your healthcare provider if you experience fever, chills, cough, yellowing of skin, joint pain or swelling during this treatment.
Q 2. Is it safe to use Suregraft 0.50mg Tablet during pregnancy?
Suregraft 0.50mg Tablet have the tendency to cause harm to unborn fetus. Inform your healthcare provider before starting this treatment if you are pregnant, or have a partner who can become pregnant. Your health care provider will conduct a pregnancy test before you start treatment with Suregraft 0.50mg Tablet.
Q 3. What are the side effects of Suregraft 0.50mg Tablet?
The common side effects that are likely to occur while you are on the treatment with Suregraft 0.50mg Tablet are fever, chills, skin Rash, joint pain, swelling, tiredness, loss of appetite, high risk of infection, mouth ulcers, difficulty breathing.
Q 4. Is it safe to undergo surgery while on treatment with Suregraft 0.50mg Tablet?
Suregraft 0.50mg Tablet may lead to poor wound healing ability. Therefore, it is advisable to tell your physician if you plan to have any surgery before starting or during treatment with Suregraft 0.50mg Tablet. Consult your healthcare provider and stop taking Suregraft 0.50mg Tablet at least one week before planned surgery.
Q 5. Can I drink alcohol while taking Suregraft 0.50mg Tablet?
It is generally recommended to avoid drinking alcohol while taking Suregraft 0.50mg Tablet, as alcohol can increase the risk of liver damage.
Fact Box of Suregraft 0.50mg Tablet
Molecule name: Everolimus | Therapeutic class: Antineoplastics |
Pharmacological class: mTOR inhibitors | Indications: 1.Advanced breast cancer 2.Advanced renal cell carcinoma 3.Advanced pancreatic neuroendocrine tumours 4.Treatment of subependymal giant cell astrocytoma |
References
- Accord Healthcare Limited, Electronic medicines compendium (EMC), [ Revised on Oct 2020] [ Accessed on 18th March 2023], https://www.medicines.org.uk/emc/files/pil.11084.pdf
- Jan Hasskarl; Everolimus; Recent Results in Cancer Research; Published on 2018; Accessed on 18/03/2023; https://pubmed.ncbi.nlm.nih.gov/30069763/
- Novartis Pharmaceuticals Corporation, US Food and Drug Administration, [ Revised on July 2012] [ Accessed on 18th March 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022334s016lbl.pdf
- Goodman & Gilman’s, The Pharmacological Basis of Therapeutics, Targeted therapy: tyrosine kinase inhibitors, monoclonal antibodies, and cytokines, 12th edition, 2011, 1743.
- KD Tripathi, Essentials of Medical Pharmacology, Immunosuppressant drugs, 7th edition, 2013, 878 - 882.
Disclaimer
MrMed’s primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on MrMed. Our mission is to support, not replace, the doctor-patient relationship.
